Ivonescimab

Name: Ivonescimab in EGFR-mutated non-small-cell lung cancer: EGFR/MET bispecific antibodies
Published: 2026-09-14T15:39:06-04:00

EGFR-mutated non-small-cell lung cancer

Manufacturer: Summit Therapeutics
Regulatory submission: BLA submitted in the fourth quarter of 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Approaches to treatment Current treatment options and standard of care

EGFR/MET bispecific antibodies

2 evidence topics · 2 sources

First-line combination option

“lazertinib combined with amivantamab” (opens the source at this quote in a new tab)

Treatment alternatives: amivantamab with chemotherapy

“amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed” (opens the source at this quote in a new tab)
“whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor.” (opens the source at this quote in a new tab)